Top

International Ophthalmology

Published in:

01-12-2024 | Metformin | Original Paper

Association between metformin use and the risk of developing open-angle glaucoma among patients with diabetes: a retrospective cohort study and meta-analysis

Authors: Hong Kyu Kim, Wanhyung Lee, Ik Hee Ryu, Jin Kuk Kim, Hyungsu Kim, Tae Keun Yoo

Published in: International Ophthalmology | Issue 1/2024

Abstract

Purpose

Recent studies examining the neuroprotective effects of metformin on open-angle glaucoma (OAG) have failed to provide consistent results. In this study, we investigated the association between metformin use and OAG.

Methods

Data were obtained from a sample cohort of the Korean National Health Insurance database. Patients diagnosed with type-2 diabetes (T2DM) between 2004 and 2013 were included. We performed propensity score-matched analysis in a matched cohort (N = 20,646). The risk of the newly developed OAG was estimated using a Cox proportional hazards model. Including the present study, the meta-analysis included five studies to calculate the pooled risk for OAG based on metformin use.

Results

In the adjusted model, the analysis revealed no statistical association between metformin use and OAG incidence (hazard ratio [HR] 1.05; 95% confidence interval [CI] 0.79–1.40; P = 0.738). The highest tercile of metformin use demonstrated no statistical significance (HR 0.93 [95% CI 0.63–1.37]; P = 0.703). No significant dose-dependent association was observed between the cumulative dose and incidence of OAG (P-value for trend = 0.336). In a meta-analysis of four published articles and the present study, the common-effects and random-effects models indicated conflicting results in terms of significance. The random effects model demonstrated no significant association (pooled risk ratio 0.53; 95% CI 0.24–1.19; P = 0.123).

Conclusion

We found no significant association between metformin use and OAG incidence in patients with T2DM in this population-based cohort study and meta-analysis. Further studies are needed to investigate the association between metformin use and the risk of OAG among patients with T2DM.

Available only for authorised users

Kwon YH, Fingert JH, Kuehn MH, Alward WLM (2009) Primary open-angle glaucoma. N Engl J Med 360:1113–1124. https://doi.org/10.1056/NEJMra0804630CrossRefPubMedPubMedCentral

Oh E, Kim YH, Ryu IH, Yoo TK (2022) The role of big data analysis in identifying a relationship between glaucoma and diabetes mellitus. Ann Transl Med 10:948. https://doi.org/10.21037/atm-22-4134CrossRefPubMedPubMedCentral

Mitchell P, Smith W, Chey T, Healey PR (1997) Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 104:712–718. https://doi.org/10.1016/S0161-6420(97)30247-4CrossRefPubMed

Bonovas S, Peponis V, Filioussi K (2004) Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis. Diabet Med 21:609–614. https://doi.org/10.1111/j.1464-5491.2004.01173.xCrossRefPubMed

Shoshani Y, Harris A, Shoja MM et al (2012) Impaired ocular blood flow regulation in patients with open-angle glaucoma and diabetes. Clin Exp Ophthalmol 40:697–705. https://doi.org/10.1111/j.1442-9071.2012.02778.xCrossRefPubMed

Ko S-H, Kim D-J, Park J-H et al (2016) Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013. Medicine (Baltimore). https://doi.org/10.1097/MD.0000000000004018CrossRefPubMedPubMedCentral

Rotermund C, Machetanz G, Fitzgerald JC (2018) The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol. https://doi.org/10.3389/fendo.2018.00400CrossRef

Chen J-L, Luo C, Pu D et al (2019) Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance. Exp Neurol 311:44–56. https://doi.org/10.1016/j.expneurol.2018.09.008CrossRefPubMed

Ping F, Jiang N, Li Y (2020) Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis. BMJ Open Diabetes Res Care 8:e001370. https://doi.org/10.1136/bmjdrc-2020-001370CrossRefPubMedPubMedCentral

10.

Lin H-C, Stein JD, Nan B et al (2015) Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol 133:915–923. https://doi.org/10.1001/jamaophthalmol.2015.1440CrossRefPubMedPubMedCentral

11.

Maleškić S, Kusturica J, Gušić E et al (2017) Metformin use associated with protective effects for ocular complications in patients with type 2 diabetes-observational study. Acta Med Acad 46:116–123. https://doi.org/10.5644/ama2006-124.196CrossRefPubMed

12.

Vergroesen JE, Thee EF, Ahmadizar F et al (2022) Association of diabetes medication with open-angle glaucoma, age-related macular degeneration, and cataract in the Rotterdam study. Jama Ophthalmol 140:674–681. https://doi.org/10.1001/jamaophthalmol.2022.1435CrossRefPubMedPubMedCentral

13.

Wang SV, Li N, Rice DS et al (2019) Using healthcare databases to refine understanding of exploratory associations between drugs and progression of open-angle glaucoma. Clin Pharmacol Ther 106:874–883. https://doi.org/10.1002/cpt.1490CrossRefPubMed

14.

George R, Asokan R, Vijaya L (2021) Association of metformin use among diabetics and the incidence of primary open-angle glaucoma–the Chennai eye disease incidence study. Indian J Ophthalmol 69:3336–3338. https://doi.org/10.4103/ijo.IJO_1486_21CrossRefPubMedPubMedCentral

15.

Lee J, Lee JS, Park S-H et al (2017) Cohort profile: the national health insurance service-national sample cohort (NHIS-NSC), South Korea. Int J Epidemiol 46:e15. https://doi.org/10.1093/ije/dyv319CrossRefPubMed

16.

Seo HJ, Oh HS (2021) Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark time analysis. Epidemiol Health 43:e2021103. https://doi.org/10.4178/epih.e2021103CrossRefPubMedPubMedCentral

17.

Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682. https://doi.org/10.1093/aje/kwq433CrossRefPubMed

18.

Zhan C, Miller M (2003) Administrative data based patient safety research: a critical review. Qual Saf Health Care 12:ii58–ii63. https://doi.org/10.1136/qhc.12.suppl_2.ii58CrossRefPubMedPubMedCentral

19.

Ma RCW, Chan JCN (2013) Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 1281:64–91. https://doi.org/10.1111/nyas.12098ADSCrossRefPubMedPubMedCentral

20.

Rim TH, Lee SY, Bae HW et al (2018) Increased risk of open-angle glaucoma among patients with diabetes mellitus: a 10-year follow-up nationwide cohort study. Acta Ophthalmol (Copenh) 96:e1025–e1030. https://doi.org/10.1111/aos.13805CrossRef

21.

Jung Y, Han K, Park H-YL, Park CK (2018) Type 2 diabetes mellitus and risk of open-angle glaucoma development in Koreans: an 11-year nationwide propensity-score-matched study. Diabetes Metab 44:328–332. https://doi.org/10.1016/j.diabet.2017.09.007CrossRefPubMed

22.

Wu A, Khawaja AP, Pasquale LR, Stein JD (2019) A review of systemic medications that may modulate the risk of glaucoma. Eye Lond Engl. https://doi.org/10.1038/s41433-019-0603-zCrossRef

23.

Moon JY, Kim HJ, Park YH et al (2018) Association between open-angle glaucoma and the risks of Alzheimer’s and Parkinson’s diseases in South Korea: a 10-year nationwide cohort study. Sci Rep 8:1–8. https://doi.org/10.1038/s41598-018-29557-6CrossRef

24.

Bayer AU, Keller ON, Ferrari F, Maag K-P (2002) Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. Am J Ophthalmol 133:135–137. https://doi.org/10.1016/S0002-9394(01)01196-5CrossRefPubMed

25.

Jing Y, Wu F, Li D et al (2018) Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrinol 461:256–264. https://doi.org/10.1016/j.mce.2017.09.025CrossRefPubMed

26.

Han J, Li Y, Liu X et al (2018) Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. Plos One 13:e0193031. https://doi.org/10.1371/journal.pone.0193031CrossRefPubMedPubMedCentral

27.

Weinstein G, Davis-Plourde KL, Conner S et al (2019) Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: pooled analysis from 5 cohorts. Plos One 14:e0212293. https://doi.org/10.1371/journal.pone.0212293CrossRefPubMedPubMedCentral

28.

Imfeld P, Bodmer M, Jick SS, Meier CR (2012) Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc 60:916–921. https://doi.org/10.1111/j.1532-5415.2012.03916.xCrossRefPubMed

29.

Kuan Y-C, Huang K-W, Lin C-L et al (2017) Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry 79:77–83. https://doi.org/10.1016/j.pnpbp.2017.06.002CrossRefPubMed

30.

Kapetanakis VV, Chan MPY, Foster PJ et al (2016) Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol 100:86–93. https://doi.org/10.1136/bjophthalmol-2015-307223CrossRefPubMed

31.

Choi S, Choi JA, Kwon JW et al (2018) Patterns of care for glaucoma patients in Korea from 2002 to 2013 using the national health insurance service claims data. Medicine (Baltimore). https://doi.org/10.1097/MD.0000000000012357CrossRefPubMedPubMedCentral

32.

Elam AR, Blachley TS, Stein JD (2016) Geographic variation in the use of diagnostic testing of patients with newly diagnosed open-angle glaucoma. Ophthalmology 123:522–531. https://doi.org/10.1016/j.ophtha.2015.10.017CrossRefPubMed

33.

Foster PJ, Buhrmann R, Quigley HA, Johnson GJ (2002) The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 86:238–242CrossRefPubMedPubMedCentral

34.

Koo BK, Lee C-H, Yang BR et al (2014) the incidence and prevalence of diabetes mellitus and related atherosclerotic complications in Korea: a national health insurance database study. Plos One 9:e110650. https://doi.org/10.1371/journal.pone.0110650ADSCrossRefPubMedPubMedCentral

35.

Noh J, Han K-D, Ko S-H et al (2017) Trends in the pervasiveness of type 2 diabetes, impaired fasting glucose and co-morbidities during an 8-year-follow-up of nationwide Korean population. Sci Rep 7:1–7. https://doi.org/10.1038/srep46656ADSCrossRef

36.

Bang CS, Baik GH (2019) Using big data to see the forest and the trees: endoscopic submucosal dissection of early gastric cancer in Korea. Korean J Intern Med 34:772–774. https://doi.org/10.3904/kjim.2019.170CrossRefPubMedPubMedCentral

37.

Krass I, Schieback P, Dhippayom T (2015) Adherence to diabetes medication: a systematic review. Diabet Med 32:725–737. https://doi.org/10.1111/dme.12651CrossRefPubMed

38.

Kosoko-Lasaki O, Gong G, Haynatzki G, Wilson MR (2006) Race, ethnicity and prevalence of primary open-angle glaucoma. J Natl Med Assoc 98:1626–1629PubMedPubMedCentral

Title: Association between metformin use and the risk of developing open-angle glaucoma among patients with diabetes: a retrospective cohort study and meta-analysis
Authors: Hong Kyu Kim
Wanhyung Lee
Ik Hee Ryu
Jin Kuk Kim
Hyungsu Kim
Tae Keun Yoo
Publication date: 01-12-2024
Publisher: Springer Netherlands
Keywords: Metformin
Glaucoma
Published in: International Ophthalmology / Issue 1/2024
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-024-02945-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association between metformin use and the risk of developing open-angle glaucoma among patients with diabetes: a retrospective cohort study and meta-analysis

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Exploration of AI-powered DenseNet121 for effective diabetic retinopathy detection

New advances in medical management of dry eye: optimizing treatment strategies for enhanced relief

Higher incidence of meibomian gland dysfunction in postmenopausal women with primary acquired nasolacrimal duct obstruction

Evaluation of dry eye disease and corneal epithelial mapping in patients with lower eyelid ectropion

Complications after CyPass® Micro-Stent explantation: a case series

Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort